--- a
+++ b/clusters/3009knumclusters/clust_210.txt
@@ -0,0 +1,301 @@
+Ability to swallow entrectinib intact
+Unable or unwilling to swallow napabucasin capsules daily.
+Patients must be able to swallow tablets whole
+Patients must be able to swallow capsules
+Patients unable to swallow capsules whole are not eligible; nasogastric or gastric (G) tube administration is not allowed
+Patients must be able to swallow tablets or capsules; a patient with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible
+Patients must be able to swallow whole capsules
+Patients must be able to swallow tablets
+Patients must be able to swallow tablets
+Ability to swallow abiraterone acetate tablets as a whole
+Patients must be able to swallow intact capsules
+Patients who are unable to swallow whole tablets are not eligible
+Patients who are unable to swallow intact tablets are not eligible
+Patients must be able to swallow intact tablets
+Patients must be able to swallow intact tablets
+Patients must be able to swallow intact tablets
+Patients must be able to swallow intact capsules
+Patients must be able to swallow intact tablets
+Able to swallow capsules
+Inability to swallow capsules or known gastrointestinal malabsorption
+Ability to swallow tablets
+Able to swallow ribociclib capsules
+Patients must be able to swallow tablets
+Eligible patients have a body surface area >= 0.7 m^2 AND be able to swallow whole tablets at the time of study enrollment
+Patients who are unable to swallow whole tablets are not eligible
+Patient must be able to swallow capsules
+Subjects who are unable to swallow pills
+Ability to swallow the investigational product tablets.
+Participants must be able to swallow ribociclib capsules or tablets
+Inability to swallow intact tablets
+Able to swallow capsules
+Inability or unwillingness to swallow capsules; patients with any condition that may impair the ability to swallow or absorb oral medications/investigational product including:\r\n* Any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills;\r\n* Prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel;\r\n* Active peptic ulcer disease;\r\n* Malabsorption syndrome
+Able to swallow capsules
+Inability to swallow intact tablets
+The subject is unable to swallow capsules.
+Ability to swallow pills or capsules
+Participant is unable to swallow or absorb oral tablets.
+Inability to swallow capsules
+Subject is unable to swallow pills
+Must be able to swallow ribociclib and everolimus capsules/tablets
+Inability to swallow gelatin capsules, or any medical condition that interferes with normal gastrointestinal absorption
+Must be able to swallow LEE011 and everolimus capsules/tablets
+Patients must have the ability to swallow tablets
+Patients who are unable to swallow tablets or liquid are not eligible.
+Patients must be able to swallow capsules; nasogastric or gastrostomy feeding (G) tube administration is not allowed
+The participant is unable to swallow tablets that are whole (do not crush or chew or administer via nasogastric [NG]-tube)
+Gastrointestinal disorder affecting absorption or the ability to swallow tablets
+Patients must be able to swallow tablets (or applesauce, if part of bioavailability \crushed\ six patient cohort)
+Unable or unwilling to swallow napabucasin capsules daily.
+Unable or unwilling to swallow tablets as per dosing schedule
+Subjects that cannot swallow tablets.
+Subject is unable to swallow or absorb oral tablets normally
+Ability to swallow pills/capsules
+Inability to swallow capsules, since capsules cannot be crushed or broken
+Unable or unwilling to swallow tablets or capsules
+Patients must be able to swallow capsules
+Able to swallow tablets.
+Patient must be able to swallow capsules
+Patients who are unable to swallow erlotinib tablets are not eligible
+Patients must be able to swallow whole tablets or capsules; nasogastric or gastrostomy tube (G-tube) administration is not allowed
+Patients must be able to swallow whole tablets or capsules; nasogastric or gastrostomy tube (G-tube) administration is not allowed; any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed
+Are able to swallow capsules
+Participant must be able to swallow tablets or capsules. A participant with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible.
+Patients who are unable to swallow tablets or have a gastrointestinal disease that could hinder the absorption of enzalutamide.
+Ability to swallow oral tablets without difficulty
+Unable to swallow capsules or disease significantly affecting gastrointestinal function
+Patients must be able to swallow intact tablets
+Patients who are not able to swallow intact tablets are not eligible
+Patients must be able to swallow intact capsules
+Patients must be able to swallow capsules
+Unable to swallow tablets.
+Are able to swallow capsules.
+Inability to swallow intact tablets
+Unable to swallow or take anything orally
+Unable or unwilling to swallow tablets or capsules
+Inability to swallow intact tablets
+Inability to swallow intact tablets
+Men unable to swallow pills
+Has an inability to swallow tablets or capsules
+Patients who are unable to swallow pills
+Able to swallow intact capsules
+Inability to swallow capsules, since capsules cannot be crushed or broken
+The subject is unable to swallow capsules
+Unable or unwilling to swallow tablets
+Able to swallow bicalutamide and ribociclib capsules/tablets.
+Patient must be capable of swallowing the ruxolitinib capsules (tablets)
+Be able to swallow tablets.
+Must be able to swallow pills or capsules
+The subject is unable to swallow tablets
+Ability to swallow capsules unless enrolled in Part E
+Part E: Any patient unable to swallow capsules who otherwise meet all other eligibility criteria for Part A (expansion) B, C or D
+Patients must be able to swallow whole capsules; nasogastric or gastrointestinal (G)-tube administration is not allowed
+Is unable to swallow capsules or malabsorption syndrome, disease or condition significantly affecting gastrointestinal function
+Able to swallow capsules
+Is unable to swallow capsules or malabsorption syndrome, disease or condition significantly affecting gastrointestinal function
+Are able to swallow capsules and tablets.
+Patients must be able to swallow AZD1775 capsules
+Ability to swallow and retain capsules.
+Patients must be able to swallow intact tablets; patients who cannot swallow intact tablets are not eligible
+Ability to swallow capsules
+Inability to swallow capsules, since capsules cannot be crushed or broken
+PART 2 GROUP 1 INCLUSION CRITERIA: Subjects taking capsule formulations must be able to swallow capsules
+PART 2 GROUP 2A INCLUSION CRITERIA: Subjects taking capsule formulations must be able to swallow capsules
+PART 2 GROUP 3 INCLUSION CRITERIA: Subjects taking capsule formulations must be able to swallow capsules
+Able to swallow the study drugs whole as tablets
+Patients must be able to swallow whole tablets
+Unable or unwilling to swallow tablets
+Patients unable to swallow pills.
+CAPMATINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
+CERITINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
+REGORAFENIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
+ENTRECTINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
+Patient has a condition that would prevent him or her from being able to swallow Toca FC tablets or absorb flucytosine.
+Impaired gastrointestinal (GI) function or GI disease that may alter absorption of ceritinib or inability to swallow up to five ceritinib capsules daily; although, patients unable to swallow capsules will be allowed to participate in this study, by following the specific instructions on making a slurry of the medication
+The subject is unable to swallow tablets
+Patients who are unable to swallow pills/capsules are ineligible
+Patients must be able to swallow intact capsules whole
+Inability to swallow tablets or capsules
+Patient must be able to swallow capsules
+Ability to swallow pills or capsules
+Subject is unable to swallow or absorb oral tablets normally
+Inability or unwillingness to swallow capsules
+Unable to swallow capsules
+Patients with malabsorption syndrome or other condition that would interfere with intestinal absorption; patients must be able to swallow capsules
+Unable to swallow tablets
+Patients who cannot swallow whole tablets (i.e. medication tablets)
+Unwilling or unable to swallow tablets BID
+The subject is unable to swallow tablets
+The subject is unable to swallow tablets
+COHORTS 1 AND 2: HEALTHY VOLUNTEERS: Ability to swallow capsules or tablets
+Patient must be able to swallow capsules
+Capacity to swallow
+Part E: Are able to swallow capsules or tablets
+Patients who are unable to swallow pills
+Patients who are unable to swallow oral gel capsules are not eligible
+Ability to swallow medication capsules by mouth (which may include taking nilotinib mixed in apple sauce)
+Participants must be able to swallow capsules
+The subject must be able to swallow tablets, or receive tablets crushed and/or dispensed in water via nasogastric or orogastric tube.
+Patients must be able to swallow tablets and have no significant impairment in gastrointestinal absorption
+Able to swallow capsules whole (pomalidomide capsules cannot be crushed, dissolved or broken)
+The subject is unable to swallow tablets
+Patients must be able to swallow whole capsules
+Patients must be able to swallow capsules
+Patient must be able to swallow capsules
+TUMOR BIOPSY SEQUENCING: Patients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorption (e.g., inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, malabsorption syndrome, and active peptic ulcer disease) are excluded; subjects with Crohn’s disease or a partial or complete small bowel obstruction are also excluded, as are any patients who cannot swallow tablets or capsules whole; tablets or capsules must not be crushed or chewed; nasogastric or gastrostomy tube (G-tube) administration is not allowed
+TREATMENT: Patients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorption (e.g., inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, malabsorption syndrome, and active peptic ulcer disease) are excluded; subjects with Crohn's disease or a partial or complete small bowel obstruction are also excluded, as are any patients who cannot swallow tablets or capsules whole; tablets or capsules must not be crushed or chewed; nasogastric or G-tube administration is not allowed
+Patients who are not able to swallow capsules or tablets
+The subject is unable to swallow capsules or tablets
+Inability to swallow lenalidomide capsules whole; capsules of 13-isotretinoin may be opened
+Patients must be able to swallow capsules
+Must be able to swallow ribociclib and tamoxifen capsules/tablets
+Patients unable to swallow tablets or patients with malabsorption syndrome, or any other disease significantly affecting gastrointestinal function
+Must be able to swallow ribociclib capsules
+Subject is able to swallow capsules and is able to take or tolerate oral medications on a continuous basis
+Patients must be able to swallow capsules whole
+PHASE II: Patients must be able to swallow capsules whole
+Known inability to swallow capsules
+Patients must be able to swallow tablets whole
+Patients must be able to swallow whole capsules
+Patients must be able to swallow capsules whole
+Patients who are unable to swallow pills
+Unable or unwilling to swallow tablets BID
+Patients must be able to swallow whole tablets or capsules; nasogastric or gastrostomy (G)-tube administration is not allowed; any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed
+Patients must be able to swallow capsules/tablets
+Patients who are unable to swallow pills are excluded
+Part C: Patients must be able to swallow intact capsules
+Patients must be able to swallow whole tablets; nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewed
+Patients must be able to swallow whole capsules and tolerate oral medications
+Patients unable to swallow whole capsules
+Able to swallow whole capsules
+Patients taking the capsule formulation must be able to swallow capsules; feeding tube administration is allowed for patients receiving the oral solution (OS)
+Patients must be able to take oral medications; patients must be able to swallow capsules whole without crushing or altering them in any way
+are able to swallow capsules
+Unable to swallow pills
+Patients must have the ability to swallow tablets
+Unable or unwilling to swallow tablets
+Unable to swallow tablets
+The subject is unable to swallow tablets
+Patients must be able to swallow whole capsules
+Inability to swallow capsules.
+Unable to swallow capsules or disease significantly affecting gastrointestinal function
+Patients must be able to swallow whole capsules
+Are able to swallow capsules and tablets.
+Subject is able to swallow capsules
+Unable to swallow capsules or disease significantly affecting gastrointestinal function
+Unable or unwilling to swallow BBI608 and/or BBI503 capsules daily
+Any condition causing an inability to swallow tablets.
+Unable or unwilling to swallow BBI608 capsules daily.
+Must be able to swallow lenalidomide capsules
+Unable or unwilling to swallow BBI608 capsules daily
+Are able to swallow capsules
+The subject is unable to swallow tablets
+Unable to swallow capsules
+Must be able to swallow ribociclib / placebo capsules/tablets
+Patients must be able to swallow capsules
+Inability to swallow capsules
+Patients unable to swallow tablets or patients with malabsorption syndrome, or any other disease significantly affecting gastrointestinal function
+Inability to swallow tablets
+The subject is unable to swallow tablets
+Unable to swallow tablets, or diagnosed malabsorption syndrome, or any other disease significantly affecting gastrointestinal function
+Patients must be able to swallow whole capsules
+Inability to swallow tablets or capsules
+Inability to swallow capsules.
+Able to swallow tablets
+Inability to swallow tablets
+Patients must be willing and able to swallow oral tablets
+Patients must have the ability to swallow tablets
+Inability to swallow tablets or use of a feeding tube
+Patients who are unable or unwilling to swallow tablets
+Unable or unwilling to swallow BBI608 capsules daily.
+Able to swallow capsules
+Participant is unable or unwilling to swallow tablets
+Willing to take abiraterone acetate on an empty stomach; no food should be consumed at least two hours before and for at least one hour after the dose of abiraterone acetate is taken, and should be able to swallow tablets whole, without crushing/chewing tablets
+Unable or unwilling to swallow BBI503 capsules daily
+Unable or unwilling to swallow BBI608 capsules daily.
+The subject is unable to swallow tablets
+Are able to swallow tablets
+Patients must be able to swallow tablets
+Patients with an inability to swallow tablets or capsules
+The subject is unable to swallow capsules tablets
+Patients who are unable to swallow pills
+The participant is unable to swallow capsules or tablets
+Patients who cannot swallow capsules
+Patients who are unable to swallow pills are not eligible
+Patients must be able to swallow intact capsules
+Inability to swallow capsules or known gastrointestinal malabsorption
+Unable to swallow pills
+Ability to swallow oral capsules
+Are able to swallow capsules
+Are able to swallow capsules or tablets
+Unable or unwilling to swallow the complete daily dose of ARQ 087 capsules
+Patients must be able to swallow the vorinostat capsules or have a feeding tube to allow for drug suspension
+Patients who are unable to swallow tablets
+Inability to swallow the HKI-272 capsules
+Able to swallow capsules
+Able to swallow capsules
+Inability to swallow capsules
+Ability to swallow tablets without difficulty;
+Patients must be able to swallow tablets
+Able to swallow tablets
+The subject is unable to swallow tablets
+Patients must be able to swallow whole capsules; capsules must not be crushed or chewed; capsules must not be opened
+RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patient must be able to swallow capsules whole
+NON-PROGRESSED DIPG (STRATUM 2): Patient must be able to swallow capsules whole
+Known inability to swallow up to five ceritinib (LDK378) capsules daily
+Ability to swallow intact palbociclib capsules and bicalutamide tablets
+The subject is unable to swallow tablets
+Inability to swallow oral capsules
+Unable to swallow tablets, or patients with malabsorption syndrome, or any other disease significantly affecting gastrointestinal function.
+Subject is unable to swallow capsules or tablets
+Inability or unwillingness to swallow capsules
+Patients must be able to swallow whole tablets (for MK-2206); nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewed
+Able to swallow capsules and maintain adequate hydration
+Patients will be excluded if they are unable to swallow capsules whole.
+Unable to swallow a whole tablet or capsule.
+Patients who are not able to swallow capsules or tablets
+Must be able to swallow whole capsules
+Ability to swallow tablets.
+Unable or unwilling to swallow BBI608/placebo capsules daily.
+Patients must be able to swallow capsules
+Inability or unwillingness to swallow capsules
+Patients must be able to swallow whole tablets; nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewed
+Unable or unwilling to swallow BBI608, BBI503, or sorafenib capsules or tablets
+Patients must be able to swallow tablets whole, without crushing
+Patients must be able to swallow whole capsules
+Patients must be able to swallow whole tablets; tablets must not be crushed or chewed
+The subject is unable to swallow tablets
+The subject is unable to swallow tablets
+Patients must be able to swallow whole tablets and capsules
+PHASE I: >= 3 years and =< 18 years of age at the time of study enrollment, if able to swallow whole capsules
+PHASE II: >= 2 and =< 18 years; body surface area (BSA) >= 0.55 m^2, and able to swallow whole capsules
+Inability to swallow capsules, since capsules cannot be crushed or broken
+Inability to swallow tablets for everolimus arm
+Patient must be able to swallow whole tablets
+Patients must be able to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation
+Patients must be able to swallow capsules whole; nasogastric or gastrostomy (G) tube administration is not allowed
+Able to swallow whole capsules
+Patients must be able to swallow tablets
+Patients must be able to swallow capsules
+Patients must be able to swallow tablets
+Subject is able to swallow enzalutamide capsules and comply with study requirements.
+Patients must be able to swallow either intact capsules or mini-tabs without chewing
+Must be able to swallow tablets and capsules
+Patient must have the ability to swallow multiple capsules
+Participants who are unable to swallow pills
+Able to swallow capsules
+Inability to swallow tablets
+Inability to swallow tablets
+Able to swallow oral capsules without difficulty.
+Able to swallow capsules
+Ability to swallow oral tablets
+Ability to swallow and tolerate oral tablets
+GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Patients must be able to swallow intact capsules/tablets, unless otherwise specified in the subprotocol to which they are assigned
+Patient must be able to swallow capsules (phase III only)
+Subjects must be able to swallow capsules/tablets
+Inability or unwillingness to swallow capsules
+Patients must be able to swallow whole capsules
+Unable or unwilling to swallow BBI608 capsules daily
+Subjects that are unable to swallow a tablet/pill
+Patients must be able to swallow whole tablets or capsules; nasogastric or g-tube administration is not allowed; any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed
+Unable to swallow capsules or disease significantly affecting gastrointestinal function